CN1646155A - 癌症疗法 - Google Patents

癌症疗法 Download PDF

Info

Publication number
CN1646155A
CN1646155A CNA038082047A CN03808204A CN1646155A CN 1646155 A CN1646155 A CN 1646155A CN A038082047 A CNA038082047 A CN A038082047A CN 03808204 A CN03808204 A CN 03808204A CN 1646155 A CN1646155 A CN 1646155A
Authority
CN
China
Prior art keywords
tumor
medicine
antigen
cell
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038082047A
Other languages
English (en)
Chinese (zh)
Inventor
M·L·阿什当
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImmunAid Pty Ltd
Original Assignee
ImmunAid Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3834147&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1646155(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ImmunAid Pty Ltd filed Critical ImmunAid Pty Ltd
Publication of CN1646155A publication Critical patent/CN1646155A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA038082047A 2002-02-14 2003-02-14 癌症疗法 Pending CN1646155A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPS0547 2002-02-14
AUPS0547A AUPS054702A0 (en) 2002-02-14 2002-02-14 Cancer therapy

Publications (1)

Publication Number Publication Date
CN1646155A true CN1646155A (zh) 2005-07-27

Family

ID=3834147

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038082047A Pending CN1646155A (zh) 2002-02-14 2003-02-14 癌症疗法

Country Status (9)

Country Link
US (1) US20050180971A1 (https=)
EP (2) EP2100615B1 (https=)
JP (1) JP2005523277A (https=)
CN (1) CN1646155A (https=)
AU (2) AUPS054702A0 (https=)
BR (1) BR0307661A (https=)
CA (1) CA2476366A1 (https=)
WO (1) WO2003068257A1 (https=)
ZA (1) ZA200407142B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107530419A (zh) * 2014-10-31 2018-01-02 昂考梅德药品有限公司 治疗疾病的组合疗法
CN111060687A (zh) * 2012-12-21 2020-04-24 中外制药株式会社 用于向gpc3靶向治疗剂疗法有效的患者施予的gpc3靶向治疗剂
US11760807B2 (en) 2014-05-08 2023-09-19 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228320A1 (en) * 2000-08-18 2003-12-11 Ashdown Martin Leonard Retroviral immunotherapy
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
EP1692516B1 (en) * 2003-10-24 2010-12-01 Immunaid Pty Ltd Method of therapy
AU2004283322B2 (en) * 2003-10-24 2010-09-16 Biotempus Pty Ltd Method of therapy
US20070275007A1 (en) * 2003-11-05 2007-11-29 The Government Of The United States Of America, Represented By The Secretary Of Health And Human S Carbohydrate Antigen-Nanoparticle Conjugates and Uses Thereof as Antimetastatic Agents in Treating Cancer
EP1765402A2 (en) * 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
AU2005282218B2 (en) * 2004-09-08 2012-04-12 Biotempus Pty Ltd Therapeutic strategy for treating autoimmune and degenerative diseases
JP5386083B2 (ja) * 2004-09-08 2014-01-15 イミューンネイド ピーティーワイ リミテッド 自己免疫疾患および変性疾患を治療する方法
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
ES2776406T3 (es) * 2007-07-12 2020-07-30 Gitr Inc Terapias de combinación que emplean moléculas de enlazamiento a GITR
DE102009015784A1 (de) * 2009-03-31 2010-12-02 Siemens Aktiengesellschaft In-vitro-Verfahren zur Diagnostik von Tumorerkrankungen
WO2010135781A1 (en) 2009-05-27 2010-12-02 Immunaid Pty Ltd Methods of treating diseases
HRP20211595T1 (hr) 2011-05-24 2022-01-21 BioNTech SE Individualizirana cjepiva protiv raka
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2014082729A1 (en) 2012-11-28 2014-06-05 Biontech Ag Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
SG10201912986PA (en) 2014-05-28 2020-02-27 Agenus Inc Anti-gitr antibodies and methods of use thereof
PT3151921T (pt) 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
MA44594B1 (fr) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
CA2988115A1 (en) 2015-06-03 2016-12-08 Bristol-Myers Squibb Company Anti-gitr antibodies for cancer diagnostics
AU2016297249B2 (en) 2015-07-23 2020-11-12 Inhibrx Biosciences, Inc. Multivalent and multispecific GITR-binding fusion proteins
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
BR112018010172A2 (pt) 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods for using them
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
JP7106538B2 (ja) 2016-12-07 2022-07-26 アジェナス インコーポレイテッド 抗体およびその使用方法
WO2018106862A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
CN110869392A (zh) 2017-05-16 2020-03-06 百时美施贵宝公司 用抗gitr激动性抗体治疗癌症
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308626A (en) 1985-06-28 1994-05-03 Toni N. Mariani Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
US5141867A (en) * 1987-02-02 1992-08-25 E. I. Du Pont De Nemours And Company Nucleotide sequence encoding a human immunodeficiency virus antigen
US5057423A (en) 1987-12-18 1991-10-15 University Of Pittsburgh Method for the preparation of pure LAK-active lymphocytes
US20020094542A1 (en) * 1988-04-15 2002-07-18 Peter Leskovar Drugs and methods for treating cancer
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5358852A (en) * 1992-12-21 1994-10-25 Eastman Kodak Company Use of calcium in immunoassay for measurement of C-reactive protein
ATE475668T1 (de) 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
US5939400A (en) 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
US6110898A (en) * 1996-05-24 2000-08-29 University Of Maryland, Baltimore DNA vaccines for eliciting a mucosal immune response
US20040203024A1 (en) * 1996-06-06 2004-10-14 Baker Brenda F. Modified oligonucleotides for use in RNA interference
ZA975889B (en) * 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
US6107020A (en) * 1996-09-20 2000-08-22 Roger Williams Hospital Model for protective and pathogenic roles of HIV-1 env-directed antibody dependent cellular cytotoxicity interaction with viral load, and uses thereof
US7030152B1 (en) * 1997-04-02 2006-04-18 The Brigham And Women's Hospital, Inc. Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
GB2339200B (en) * 1998-06-06 2001-09-12 Genostic Pharma Ltd Genostics
US20030228320A1 (en) * 2000-08-18 2003-12-11 Ashdown Martin Leonard Retroviral immunotherapy
AUPQ948800A0 (en) 2000-08-18 2000-09-07 Immunaid Pty Ltd A vaccine strategy
US20060134713A1 (en) * 2002-03-21 2006-06-22 Lifescan, Inc. Biosensor apparatus and methods of use
ES2334125T3 (es) * 2002-11-04 2010-03-05 University Of Massachusetts Interferencia de arn especifico de alelos.
EP2347767A3 (en) * 2003-01-31 2013-06-12 Albor Biologics, Inc. Immune regulation based on the targeting of early activation molecules
EP1692516B1 (en) * 2003-10-24 2010-12-01 Immunaid Pty Ltd Method of therapy
JP5386083B2 (ja) * 2004-09-08 2014-01-15 イミューンネイド ピーティーワイ リミテッド 自己免疫疾患および変性疾患を治療する方法
US7721198B2 (en) * 2006-01-31 2010-05-18 Microsoft Corporation Story tracking for fixed layout markup documents
GB2436616A (en) * 2006-03-29 2007-10-03 Inverness Medical Switzerland Assay device and method
WO2010135781A1 (en) * 2009-05-27 2010-12-02 Immunaid Pty Ltd Methods of treating diseases

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111060687A (zh) * 2012-12-21 2020-04-24 中外制药株式会社 用于向gpc3靶向治疗剂疗法有效的患者施予的gpc3靶向治疗剂
US11760807B2 (en) 2014-05-08 2023-09-19 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy
CN107530419A (zh) * 2014-10-31 2018-01-02 昂考梅德药品有限公司 治疗疾病的组合疗法

Also Published As

Publication number Publication date
WO2003068257A1 (en) 2003-08-21
BR0307661A (pt) 2005-02-22
ZA200407142B (en) 2005-11-30
EP1482970A4 (en) 2006-01-18
EP2100615B1 (en) 2016-02-10
EP2100615A1 (en) 2009-09-16
CA2476366A1 (en) 2003-08-21
AU2003203051A1 (en) 2003-09-04
AU2003203051B2 (en) 2007-10-25
US20050180971A1 (en) 2005-08-18
JP2005523277A (ja) 2005-08-04
EP1482970A1 (en) 2004-12-08
AUPS054702A0 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
CN1646155A (zh) 癌症疗法
JP6246252B2 (ja) 癌の補助薬物療法でリステリアを使用する方法および組成物
CN1184320C (zh) Mhc－ⅱ类配体作为疫苗佐剂以及lag－3用于癌症治疗的应用
CN1250285C (zh) 被称作胞外体的细胞囊泡,其制备方法及在免疫刺激中的用途
CN1805758B (zh) 核酸和细胞疫苗的组分
AU2016281958A1 (en) Manufacturing device and process for personalized delivery vector-based immunotherapy
CN1291755C (zh) 增强低免疫原性抗原的免疫原性的药物组合物
CN1705739A (zh) 用作抗原递送系统的抗原转导的t细胞
KR102833272B1 (ko) 변형된 효모-브라큐리 면역치료학적 조성물
JP7384896B2 (ja) 主要組織適合遺伝子複合（ｍｈｃ）クラスｉｉ－発現癌細胞ワクチン、及び統合免疫応答を生じさせるための使用方法
AU2014227019B2 (en) Novel peptide having 5 linked CTL epitopes
KR20080042097A (ko) 수포에 담긴 불완전 리보솜 생성물（ＤＲｒｉｂｂｌｅ） 및면역 반응을 자극하기 위해 이를 이용하는 방법
CN1469746A (zh) 逆转录病毒免疫疗法
RU2495677C2 (ru) Сочетание рекомбинантной микробактерии и биологически активного средства в качестве вакцины
CN1291105A (zh) 半抗原修饰的肿瘤细胞膜和制备及应用半抗原修饰的肿瘤细胞膜的方法
CN1960744A (zh) 肽IL1β和TNFα以及应用其治疗的方法
US11419901B2 (en) Porphyromonas gingivalis immune modulators and uses thereof
Rousseau et al. Vaccine therapies for pediatric malignancies
US20230210970A1 (en) Heterologous combination prime:boost therapy and methods of treatment
JP2010515670A (ja) 癌治療のための、手術、化学療法または放射線療法と併用した免疫療法におけるｍａｇｅａ３−プロテインｄ融合抗原の使用
WO2018058490A1 (zh) Col14a1衍生的肿瘤抗原多肽及其应用
Miller et al. From breast cancer immunobiology to her-2 DNA vaccine and autoimmune sequelae
CN118403154A (zh) 一种抗癌药物组合物及其应用
HK1063726B (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
HK1081227A (en) Antigen transduced t cells used as a delivery system for antigens

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20050727